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Introduction {#jah32046-sec-0004}
============

Cardiovascular disease is the major cause of morbidity and mortality for individuals with diabetes mellitus and is the largest contributor to the direct and indirect costs of diabetes mellitus.[1](#jah32046-bib-0001){ref-type="ref"} Hypertension is an important cardiovascular risk factor in diabetics, affecting more than half of the patients with type 2 diabetes mellitus (T2D). Several studies have demonstrated the beneficial effects of controlling cardiovascular risk factors in people with diabetes to reduce cardiovascular events.[2](#jah32046-bib-0002){ref-type="ref"}, [3](#jah32046-bib-0003){ref-type="ref"} However, observational studies have demonstrated that there is often poor control of other cardiovascular risk factors in patients with diabetes[4](#jah32046-bib-0004){ref-type="ref"}, [5](#jah32046-bib-0005){ref-type="ref"}; hence, a more proactive approach to cardiovascular risk factor management is required in this population. This may necessitate multiple drugs being prescribed, and polypharmacy may have a negative impact on observance. One approach to addressing this is the use of a combination pill, or "polypill."[6](#jah32046-bib-0006){ref-type="ref"} Another approach would be to use compounds that have beneficial pleiotropic properties.

The sodium‐glucose cotransporter 2 (SGLT2) inhibitors are a class of oral hypoglycemic agents that act primarily by increasing the elimination of glucose in the urine. Two agents of this class, dapagliflozin and canagliflozin, are currently approved for marketing in the United States and Europe. In addition to glucose lowering, SGLT2 inhibitors have been reported to be associated with weight loss and to act as osmotic diuretics, resulting in lowering of blood pressure (BP).[7](#jah32046-bib-0007){ref-type="ref"} Therefore, SGLT2 inhibitors could be used to simultaneously improve diabetic control while also lowering BP. However, the putative effects of SGLT2 inhibitors on BP are still contested. Moreover, the individual studies to date have been limited by sample size, research design, and subject traits (sex, ethnicity, age, etc) and have therefore been underpowered to achieve a reliable conclusion. Meta‐analysis has the benefit of overcoming these limitations by increasing the sample size. We therefore conducted a systematic review and meta‐analysis to determine the effect of SGLT2 inhibitors on BP levels in people with T2D based on available randomized controlled trials (RCTs).

Materials and Methods {#jah32046-sec-0005}
=====================

Literature Search Strategy {#jah32046-sec-0006}
--------------------------

The present study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines.[8](#jah32046-bib-0008){ref-type="ref"}, [9](#jah32046-bib-0009){ref-type="ref"} The study protocol was registered with the International Prospective Register of Systematic Reviews, PROSPERO (registration no. CRD42016038789). The primary exposure of interest was the effect of treatment with SGLT2 inhibitors, compared either with placebo or active drugs, on BP.

We searched multiple databases including PUBMED‐MEDLINE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Science, SCOPUS, and Google Scholar. To achieve maximum sensitivity of the search strategy and identify all randomized control trials, we combined sodium‐glucose cotransport‐2, SGLT2 inhibitor, canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, remogliflozin, sergliflozin, tofogliflozin, ASP1941, AVE2268, BI‐10773, BMS512148, KGT‐1681, TA‐7284, TS‐033, YM543, hypertension, high BP, systolic hypertension, diastolic hypertension, and hypertension as either keywords or MeSH terms (Tables [S1](#jah32046-sup-0001){ref-type="supplementary-material"} and [S2](#jah32046-sup-0001){ref-type="supplementary-material"}). The wild‐card term "\*" was used to increase the sensitivity of the search strategy. No language restriction was applied. This search strategy was further supplemented with hand searching of reference lists of included articles and through tracking the citations of eligible references in Google Scholar.

To further minimize the effect of publication bias, a snowball method, characterized by manual checking of references from retrieved articles, was applied in order to ensure complete collection. Furthermore, completed but yet unpublished studies with the drugs specified above were searched in the [www.clinicaltrials.gov](http://www.clinicaltrials.gov) register. Results of unpublished trials were retrieved, if available, on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) or [www.clinicalstudyresults.org](http://www.clinicalstudyresults.org) as well as Food and Drug Administration and European Medicines Agency ([www.ema.europa.eu](http://www.ema.europa.eu)) reviews of approved drugs. All these sources were also used to complete information on results of published trials when not reported in publications (including the primary trial publications, and subsequent reviews and/or pooled analyses reporting data on individual trials). To maximize the sensitivity we searched until April 2016. Two researchers (M.M., P.R.) independently searched the database with these search terms to ensure that none of the relevant studies was missed.

### Selection Criteria {#jah32046-sec-0007}

We included all RCTs that evaluated the use of an SGLT2 inhibitor on the parameters of interest in patients with T2D (comparing SGLT2 inhibitors with placebo or active drugs \[oral hypoglycemic agents and/or insulin\] different from other SGLT2 inhibitors). Eligible studies had to meet the following criteria: (1) controlled trials with either parallel or crossover design; (2) presentation of sufficient information on primary outcome at baseline and at the end of follow‐up in each group or providing the net change values. Exclusion criteria were these: (1) nonclinical studies; (2) observational studies with case‐control, cross‐sectional, or cohort design; and (3) studies that did not provide data on the levels of the outcomes of interest at baseline and/or at the end of trial. Narrative reviews, comments, opinion pieces, methodological publications, editorials, letters, or any other publications lacking primary data and/or explicit method descriptions, were also excluded. No newspaper and magazine articles (from the hand search of references) were included.

### Data Extraction and Critical Appraisal {#jah32046-sec-0008}

Initially, duplicate studies were removed, followed by screening of the titles and abstracts by 2 reviewers. To avoid bias, these reviewers were blinded to names, qualifications, or the institutional affiliations of the study authors during data extraction and in making decisions on inclusion or exclusion (the agreement between the researchers was excellent \[κ index 0.86; *P*\<0.001\]). Studies were then either (1) excluded, (2) included, or (3) marked as "pending" if the reviewer was unsure about their eligibility for inclusion. Contradictory judgments or pending studies were temporarily included and moved to the next phase of review of full texts. Once full texts had been retrieved, 2 reviewers independently applied inclusion and exclusion criteria, based on quick assessments of the full texts. Disagreements were resolved at a meeting between reviewers prior to the selected articles being retrieved. Based on PRISMA guidelines, a flow chart was produced to facilitate transparency of the process (Figure [1](#jah32046-fig-0001){ref-type="fig"}). To avoid duplication, for multiple publications that appeared to originate from an overlapping data set that comprised accumulating numbers of patients or increased lengths of follow‐up, only the most recent complete reports were included for quantitative assessment at each time interval.

![PRISMA flow chart for study selection.](JAH3-6-e004007-g001){#jah32046-fig-0001}

### Quality Assessment {#jah32046-sec-0009}

A systematic assessment of bias in the included RCTs was performed using the Cochrane criteria.[10](#jah32046-bib-0010){ref-type="ref"}, [11](#jah32046-bib-0011){ref-type="ref"} The items used for the assessment of each study were the following: adequacy of random sequence generation, allocation concealment, blinding of participants, personnel and outcomes assessment, handling of dropouts (incomplete outcome data), selective outcome reporting, and other potential sources of bias.[10](#jah32046-bib-0010){ref-type="ref"}, [12](#jah32046-bib-0012){ref-type="ref"} According to the recommendations of the Cochrane Handbook, a judgment of "yes" indicated a low risk of bias, whereas "no" indicated a high risk of bias.[10](#jah32046-bib-0010){ref-type="ref"} Labeling an item as "unclear" indicated an unclear or unknown risk of bias.[10](#jah32046-bib-0010){ref-type="ref"} Disagreements were resolved by discussion and consensus in consultation with a third author (A.P.K.) to resolve persistent inconsistencies.

### Data Extraction and Management {#jah32046-sec-0010}

The full text of studies meeting inclusion criteria were retrieved and screened to determine eligibility by 2 reviewers (M.M., P.R.). Following assessment of methodological quality, 2 reviewers extracted data onto a purpose‐designed data extraction form and independently summarized what they considered to be the most important results from each study. These summaries were compared, and differences were resolved by discussion and consultation with a third reviewer (A.P.K.). Any further calculations on study data considered were conducted by the first reviewer and checked by the second reviewer. Data were sorted by first author, year of publication, country of the study, design, age range of the participants, total sample size, SGLT2 inhibitor, comparator, number of patients, dosage, and follow‐up duration (Table [1](#jah32046-tbl-0001){ref-type="table-wrap"}).[13](#jah32046-bib-0013){ref-type="ref"}, [14](#jah32046-bib-0014){ref-type="ref"}, [15](#jah32046-bib-0015){ref-type="ref"}, [16](#jah32046-bib-0016){ref-type="ref"}, [17](#jah32046-bib-0017){ref-type="ref"}, [18](#jah32046-bib-0018){ref-type="ref"}, [19](#jah32046-bib-0019){ref-type="ref"}, [20](#jah32046-bib-0020){ref-type="ref"}, [21](#jah32046-bib-0021){ref-type="ref"}, [22](#jah32046-bib-0022){ref-type="ref"}, [23](#jah32046-bib-0023){ref-type="ref"}, [24](#jah32046-bib-0024){ref-type="ref"}, [25](#jah32046-bib-0025){ref-type="ref"}, [26](#jah32046-bib-0026){ref-type="ref"}, [27](#jah32046-bib-0027){ref-type="ref"}, [28](#jah32046-bib-0028){ref-type="ref"}, [29](#jah32046-bib-0029){ref-type="ref"}, [30](#jah32046-bib-0030){ref-type="ref"}, [31](#jah32046-bib-0031){ref-type="ref"}, [32](#jah32046-bib-0032){ref-type="ref"}, [33](#jah32046-bib-0033){ref-type="ref"}, [34](#jah32046-bib-0034){ref-type="ref"}, [35](#jah32046-bib-0035){ref-type="ref"}, [36](#jah32046-bib-0036){ref-type="ref"}, [37](#jah32046-bib-0037){ref-type="ref"}, [38](#jah32046-bib-0038){ref-type="ref"}, [39](#jah32046-bib-0039){ref-type="ref"}, [40](#jah32046-bib-0040){ref-type="ref"}, [41](#jah32046-bib-0041){ref-type="ref"}, [42](#jah32046-bib-0042){ref-type="ref"}, [43](#jah32046-bib-0043){ref-type="ref"}, [44](#jah32046-bib-0044){ref-type="ref"}, [45](#jah32046-bib-0045){ref-type="ref"}, [46](#jah32046-bib-0046){ref-type="ref"}, [47](#jah32046-bib-0047){ref-type="ref"}, [48](#jah32046-bib-0048){ref-type="ref"}, [49](#jah32046-bib-0049){ref-type="ref"}, [50](#jah32046-bib-0050){ref-type="ref"}, [51](#jah32046-bib-0051){ref-type="ref"}, [52](#jah32046-bib-0052){ref-type="ref"}, [53](#jah32046-bib-0053){ref-type="ref"}, [54](#jah32046-bib-0054){ref-type="ref"}, [55](#jah32046-bib-0055){ref-type="ref"}

###### 

General Characteristics of the Studies Included

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First Author, Year of Pub                                         Country       Age Range, y   Total Sample Size   Male (%)      Sodium‐Glucose Cotransporter 2 Inhibitor   Comparator             Background Treatment   Follow‐Up Duration (weeks)
  ----------------------------------------------------------------- ------------- -------------- ------------------- ------------- ------------------------------------------ ---------------------- ---------------------- ----------------------------
  Rosenstock, 2012[13](#jah32046-bib-0013){ref-type="ref"}          USA           ≥18            451                 52%           Canagliflozin                              Placebo                Metformin              12

  Rosenstock, 2012[14](#jah32046-bib-0014){ref-type="ref"}          USA           ≥18            420                 208 (49.5)    Dapagliflozin                              Placebo+pioglitazone   Pioglitazone           48

  Henry, 2012[15](#jah32046-bib-0015){ref-type="ref"}               USA           18 to 77       814                 376 (46.1)    Dapagliflozin                              Placebo+metformin      Metformin              24

  Kashiwagi, 2015[16](#jah32046-bib-0016){ref-type="ref"}           Japan         20 to 74       164                 128 (78)      Ipragliflozin                              Placebo                                       

  Bailey, 2010[17](#jah32046-bib-0017){ref-type="ref"}              UK            18 to 77       546                 292 (53.4)    Dapagliflozin                              Placebo                                       24

  Bailey, 2015[18](#jah32046-bib-0018){ref-type="ref"}              UK            18 to 77       278                 141 (50.7)    Dapagliflozin                              Placebo                                       24

  Bailey, 2013[19](#jah32046-bib-0019){ref-type="ref"}              UK            18 to 77       168                               Dapagliflozin                              Placebo+metformin      Metformin              102

  Devineni, 2012[20](#jah32046-bib-0020){ref-type="ref"}            USA           18 to 65       27                  15 (55.5)     Canagliflozin                              Placebo                                       4

  Ferrannini, 2013[21](#jah32046-bib-0021){ref-type="ref"}          Italy         18 to 79       326                 172 (52.7)    Empagliflozin                              Placebo                                       12

  Ferrannini, 2010[22](#jah32046-bib-0022){ref-type="ref"}          Italy         18 to 77       274                 132 (48.1)    Dapagliflozin                              Placebo                                       24

  Lavalle‐González, 2013[23](#jah32046-bib-0023){ref-type="ref"}    Mexico        18 to 80       918                 433 (47.1)    Canagliflozin                              Placebo+sitagliptin                           26

  Schernthaner, 2013[24](#jah32046-bib-0024){ref-type="ref"}        Austria       ≥18            755                 422 (55.9)    Canagliflozin                              Sitagliptin                                   52

  Lambers Heerspink, 2013[25](#jah32046-bib-0025){ref-type="ref"}   Netherlands   18 to 70       49                  34 (69.3)     Dapagliflozin                              Placebo                                       12

  Yamout, 2014[26](#jah32046-bib-0026){ref-type="ref"}              USA           18 to 80       1036                634 (61.1)    Canagliflozin                              Placebo                                       26

  Häring, 2013[27](#jah32046-bib-0027){ref-type="ref"}              Germany       ≥18            533                 339 (63.6)    Empagliflozin                              Placebo                                       24

  Tikkanen, 2015[28](#jah32046-bib-0028){ref-type="ref"}            Finland       ≥1             823                 495 (60.1)    Empagliflozin                              Placebo                                       12

  Bolinder, 2014[29](#jah32046-bib-0029){ref-type="ref"}            Sweden        30 to 75       109                               Dapagliflozin                              Placebo+metformin      Metformin              102

  Wilding, 2013[30](#jah32046-bib-0030){ref-type="ref"}             UK            18 to 80       460                 239 (51.0)    Canagliflozin                              Placebo                                       52

  Wilding, 2014[31](#jah32046-bib-0031){ref-type="ref"}             UK            18 to 80       800                 382 (47.7)    Dapagliflozin                              Placebo+insulin        Insulin                104

  Rosenstock, 2013[32](#jah32046-bib-0032){ref-type="ref"}          USA           18 to 80       424                 212 (50)      Empagliflozin                              Placebo                                       12

  Yale, 2013[33](#jah32046-bib-0033){ref-type="ref"}                Canada        ≥25            269                 163 (60.6)    Canagliflozin                              Placebo                                       26

  List, 2009[34](#jah32046-bib-0034){ref-type="ref"}                Canada        18 to 79       297                 169 (56.9)    Dapagliflozin                              Placebo                                       12

  Bolinder, 2011[35](#jah32046-bib-0035){ref-type="ref"}            Sweden        30 to 75       182                 100 (54.9)    Dapagliflozin                              Placebo+metformin      Metformin              24

  Wilding, 2012[36](#jah32046-bib-0036){ref-type="ref"}             UK            18 to 80       800                 382 (47.7)    Dapagliflozin                              Placebo+insulin        Insulin                48

  Kaku, 2014[37](#jah32046-bib-0037){ref-type="ref"}                Japan         ≥20            261                 155 (59.3)    Dapagliflozin                              Placebo                                       24

  Kaku, 2013[38](#jah32046-bib-0038){ref-type="ref"}                Japan         18 to 79       279                               Dapagliflozin                              Placebo                                       12

  Stenlof, 2013[39](#jah32046-bib-0039){ref-type="ref"}             Sweden        18 to 80       584                 258 (44.2)    Canagliflozin                              Placebo                                       26

  Strojek, 2011[40](#jah32046-bib-0040){ref-type="ref"}             Poland        ≥18            592                 285 (48.1)    Dapagliflozin                              Placebo+glimepiride    Glimepiride            24

  Leiter, 2015[41](#jah32046-bib-0041){ref-type="ref"}              Canada        18 to 80       1450                              Canagliflozin                              Glimepiride                                   104

  Leiter, 2014[42](#jah32046-bib-0042){ref-type="ref"}              Canada        18 to 80       962                 644 (66.9)    Dapagliflozin                              Placebo                                       52

  Ji, 2014[43](#jah32046-bib-0043){ref-type="ref"}                  China         ≥18            376                               Dapagliflozin                              Placebo                                       24

  Weber, 2016[44](#jah32046-bib-0044){ref-type="ref"}               USA           ···            449                 247 (55)      Dapagliflozin                              Placebo                                       12

  Nauck, 2011[45](#jah32046-bib-0045){ref-type="ref"}               Germany       ≥18            814                 449 (55.1)    Dapagliflozin                              Placebo+metformin      Metformin              52

  Inagaki, 2013[46](#jah32046-bib-0046){ref-type="ref"}             Japan         20 to 80       382                 260 (68.1)    Canagliflozin                              Placebo                                       12

  Neal, 2015[47](#jah32046-bib-0047){ref-type="ref"}                Australia     ≥30            2072                1366 (65.9)   Canagliflozin                              Placebo                                       52

  Inagaki, 2014[48](#jah32046-bib-0048){ref-type="ref"}             Japan         ≥20            271                 191 (70.5)    Canagliflozin                              Placebo                                       24

  Schumm‐Draeger, 2015[49](#jah32046-bib-0049){ref-type="ref"}      Germany       18 to 77       399                               Dapagliflozin                              Placebo+metformin      Metformin              16

  Sha, 2014[50](#jah32046-bib-0050){ref-type="ref"}                 USA           25 to 70       36                  31 (86.1)     Canagliflozin                              Placebo                                       12

  Del Prato, 2015[51](#jah32046-bib-0051){ref-type="ref"}           Italy                        299                               Dapagliflozin                              Glipizide+metformin    Metformin              208

  Matthaei, 2015[52](#jah32046-bib-0052){ref-type="ref"}            Germany       ≥18            216                 90 (41.6)     Dapagliflozin                              Placebo                                       24

  Forst, 2014[53](#jah32046-bib-0053){ref-type="ref"}               Germany       18 to 80       342                 216 (63.2)    Canagliflozin                              Placebo+sitagliptin    ···                    52

  Sykes, 2015[54](#jah32046-bib-0054){ref-type="ref"}               UK            18 to 70       276                 165 (59.7)    Remogliflozin etabonate                    Placebo                                       12

  Skyes, 2015[55](#jah32046-bib-0055){ref-type="ref"}               UK            18 to 70       205                 99 (48.2)     Remogliflozin etabonate (once daily)\      Placebo                                       12
                                                                                                                                   Remogliflozin etabonate (twice daily)                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data Synthesis {#jah32046-sec-0011}
--------------

Based on the recommendations of the Cochrane Handbook, the mean change from baseline in the levels of outcome variables of interest and standard deviations (SD) for both intervention and control groups were used to calculate the effect size.[56](#jah32046-bib-0056){ref-type="ref"} In brief, the net changes in measurements (change scores) were calculated as (measure at end of follow‐up)−(measure at baseline). For RCTs, change scores were calculated as (\[measure at end of follow‐up in the treatment group\]−\[measure at baseline in the treatment group\])−(\[measure at end of follow‐up in the control group\]−\[measure at baseline in the control group\]). Where only standard error of the mean was reported, the SD was estimated as SD=(standard error of the mean)×(square root of n), where n is the number of subjects.[57](#jah32046-bib-0057){ref-type="ref"} If the outcome measures were reported as median and range (or 95% CI), mean and SD values were estimated using the method described by Hozo et al.[58](#jah32046-bib-0058){ref-type="ref"} When the outcome variable was available only in the graphic form, the software GetData Graph Digitizer 2.24 was used to digitize and extract the data.[59](#jah32046-bib-0059){ref-type="ref"} Blood lipid and glucose levels were collated in millimoles per liter; a multiplication factor of 0.0259, 0.0113, or 0.0555 was used to convert cholesterol (total cholesterol, high‐density lipoprotein, or low‐density lipoprotein), triglycerides, and glucose levels, respectively, from milligrams per deciliter to millimoles per liter as appropriate.[57](#jah32046-bib-0057){ref-type="ref"}

A random‐effects model (using the DerSimonian‐Laird method) and the generic inverse variance method were used to derive pooled estimates across studies.[60](#jah32046-bib-0060){ref-type="ref"} Heterogeneity was quantitatively assessed using the I^2^ index,[60](#jah32046-bib-0060){ref-type="ref"} which measures the extent of true heterogeneity.[61](#jah32046-bib-0061){ref-type="ref"} It can be interpreted as the percentage of the total variability in a set of effect sizes due to true heterogeneity, that is, to between‐studies variability.[61](#jah32046-bib-0061){ref-type="ref"} Low, moderate, and high I^2^ values are 25%, 50%, and 75%, respectively.[60](#jah32046-bib-0060){ref-type="ref"} When heterogeneity is substantial, a prediction interval rather than a confidence interval can help to provide a better sense of the uncertainty around the effect estimate.[61](#jah32046-bib-0061){ref-type="ref"}

Effect sizes were expressed as weighed mean difference (WMD) and CI. In order to evaluate the influence of each study on the overall effect size, a sensitivity analysis was conducted using the leave‐1‐out method (ie, removing 1 study each time and repeating the analysis).[62](#jah32046-bib-0062){ref-type="ref"}, [63](#jah32046-bib-0063){ref-type="ref"}, [64](#jah32046-bib-0064){ref-type="ref"}

Publication Bias {#jah32046-sec-0012}
----------------

Potential publication bias was explored using visual inspection of the Begg funnel plot asymmetry, the Begg rank correlation, and Egger weighted regression tests. The Duval and Tweedie trim‐and‐fill" and fail‐safe N methods were used to adjust the analysis for the effects of publication bias.[65](#jah32046-bib-0065){ref-type="ref"} Meta‐analysis was conducted using Comprehensive Meta‐Analysis (CMA) V3 software (Biostat, Englewood, NJ).[66](#jah32046-bib-0066){ref-type="ref"}

Results {#jah32046-sec-0013}
=======

Summary of Searches and Study Selection Process {#jah32046-sec-0014}
-----------------------------------------------

A total of 425 unique citations were identified through searches, of which 329 records remained after removal of duplicates. After screening via titles and abstracts, 55 articles remained for further evaluation; of these, several were excluded for the following reasons: nonhuman, or genetic and molecular studies (n=4), review articles (n=4), editorial articles (n=2), and nonrandomized clinical trials (n=2) (Figure [1](#jah32046-fig-0001){ref-type="fig"}). Therefore, 43 studies were finally included in the meta‐analysis.

### Risk of Bias Assessment {#jah32046-sec-0015}

There was unclear risk of bias in some items, including allocation concealment, blinding of participants and personnel, blinding of outcome assessment, random sequence generation, incomplete outcome data, and other biases. Four studies had moderate risk of bias,[13](#jah32046-bib-0013){ref-type="ref"}, [17](#jah32046-bib-0017){ref-type="ref"}, [26](#jah32046-bib-0026){ref-type="ref"}, [36](#jah32046-bib-0036){ref-type="ref"} whereas other studies evaluated had a low risk of bias based on selective outcome reporting. Details of the quality of bias assessment are shown in Table [S3](#jah32046-sup-0001){ref-type="supplementary-material"}.

Characteristics of the Included Studies {#jah32046-sec-0016}
---------------------------------------

The characteristics of the included studies are summarized in Table [1](#jah32046-tbl-0001){ref-type="table-wrap"}. These studies were published between 2008 and 2015 from 14 countries including the United States of America (8 studies), United Kingdom (8 studies), Japan (5 studies), Germany (5 studies), Canada (4 studies), Italy (3 studies), Sweden (3 studies), and 1 study from each of Mexico, Austria, Netherlands, Finland, Poland, China, and Australia. The number of participants included in studies ranged from 27[20](#jah32046-bib-0020){ref-type="ref"} to 2072.[47](#jah32046-bib-0047){ref-type="ref"} All of these studies were randomized clinical trials with durations of 4 weeks (1 trial), 12 weeks (12 trials), 24 weeks (11 trials), 26 weeks (4 trials), 48 weeks (2 trials), 52 weeks (7 trials), 102 weeks (2 trials), 104 weeks (2 trials), and 208 weeks (1 trial). The SGLT2 inhibitors studied were dapagliflozin (22 trials), canagliflozin (14 trials), empagliflozin (4 trials), remogliflozin (2 trials), and pragliflozin (1 trial). SGLT2 inhibitors were compared with placebo (42 trials), metformin (7 trials), sitagliptin (3 trials), pioglitazone (1 trial), glimepiride (2 trials), and glipizide (1 trial). The participants in 8 trials received metformin as the only background antidiabetic therapy, and in other studies, participants were on background treatments with pioglitazone (2 trials), insulin (2 trials), and glimepiride (1 trial). The major demographic and clinical features were expressed as mean±SD, and the age of the participants ranged from 1 to 80 years.

The average follow‐up time by SGLT2 ranged from 4 to 104 weeks (median 26 weeks) in studies using canagliflozin, 12 to 52 weeks (median 12 weeks) in studies using empaglifozin, 12 to 208 weeks (median 24 weeks) in studies using dapagliflozin, 12 weeks in the 2 studies using remogliflozin, and 24 weeks in the single study using pragliflozin.

Pooled Estimate of the Effect of SGLT2 Therapy on Systolic and Diastolic Blood Pressure {#jah32046-sec-0017}
---------------------------------------------------------------------------------------

The pooled estimate (WMD) of the effect of SGLT2 on systolic BP (SBP) levels was −2.46 mm Hg (95% CI −2.86 to −2.06, I^2^ 62.1%) across all studies; −2.23 mm Hg (95% CI −2.28 to −2.18, I^2^ 48.1%) across studies using canagliflozin; −1.03 mm Hg (95% CI −1.09 to −0.97, I^2^ 47.2%) across studies using dapagliflozin; and −2.59 mm Hg (95% CI −2.70 to −2.49, I^2^ 45.23%) across studies using empagliflozin (Figure [2](#jah32046-fig-0002){ref-type="fig"}).

![Plot to display weighted mean differences (bars) and 95% CIs (whiskers) for the impact of SGLT2 therapy on systolic blood pressure. SGLT 2, sodium‐glucose cotransporter 2.](JAH3-6-e004007-g002){#jah32046-fig-0002}

The pooled estimate (WMD) of the effect of SGLT2 on diastolic BP (DBP) levels was −1.46 mm Hg (95% CI −1.82 to −1.09, I^2^ 56.3%) across all studies; −2.23 mm Hg (95% CI −2.30 to −2.16, I^2^ 42.3) across studies using canagliflozin; −0.72 mm Hg (95% CI −0.78 to −0.66, I^2^ 32.1%) across studies using dapagliflozin; −1.09 mm Hg (95% CI −1.18 to −1.01, I^2^ 30.0%) across studies using empagliflozin (Figure [3](#jah32046-fig-0003){ref-type="fig"}). In meta‐regression analyses, length of follow‐up did not influence the effects of SGLT2 on either SBP (β=0.0042, *P*=0.375) or DBP (β=0.0006, *P*=0.926). A summary of the effects of SGLT2 on the lipid profile, glycemia, and liver and kidney function variables is shown in Table [2](#jah32046-tbl-0002){ref-type="table-wrap"}.

![Plot to display weighted mean differences (bars) and 95% CIs (whiskers) for the impact of SGLT2 inhibitor therapy on diastolic blood pressure. SGLT 2, sodium‐glucose cotransporter 2.](JAH3-6-e004007-g003){#jah32046-fig-0003}

###### 

Summary of the Effect of SGLT2 Inhibitors on the Lipid Profile, Glycemia, and Liver and Kidney Function Variables

  Variables                              Result of the Leave‐1‐Out Sensitivity Analyses
  -------------------------------------- ----------------------------------------------------
  Triglyceride                           
  Across all studies                     −2.08 mg/dL (95% CI −2.51 to −1.64)
  Canagliflozin                          −1.02 mg/dL (95% CI −1.08 to −0.96)
  Dapagliflozin                          −0.68 mg/dL (95% CI −0.76 to −0.60)
  Empagliflozin                          −0.32 mg/dL (95% CI −0.44 to −0.20)
  Remogliflozin                          −2.82 mg/dL (95% CI −3.03 to −2.62)
  Total cholesterol                      
  Across all studies                     0.77 mg/dL (95% CI 0.33‐1.21)
  Canagliflozin                          1.61 mg/dL (95% CI 1.53‐1.68)
  Dapagliflozin                          0.41 mg/dL (95% CI 0.32‐0.50)
  Empagliflozin                          0.56 mg/dL (95% CI 0.43‐0.70)
  Remogliflozin                          0.26 mg/dL (95% CI 0.11‐0.40)
  HDL‐cholesterol                        
  Across all studies                     3.89 mg/dL (95% CI 3.23‐4.56)
  Canagliflozin                          2.14 mg/dL (95% CI 2.08‐2.20)
  Dapagliflozin                          0.57 mg/dL (95% CI 0.46‐0.67)
  Empagliflozin                          2.96 mg/dL (95% CI 2.78‐3.14)
  Remogliflozin                          3.27 mg/dL (95% CI 3.04‐3.50)
  Fasting blood glucose                  
  Across all studies                     −2.40 mg/dL (95% CI −2.68 to −2.11)
  Canagliflozin                          −0.92 mg/dL (95% CI −0.98 to −0.87)
  Dapagliflozin                          −0.75 mg/dL (95% CI −0.79 to 0.70)
  Empagliflozin                          −1.35 mg/dL (95% CI −1.45 to −1.24)
  Remogliflozin                          −0.88 mg/dL (95% CI −1.11 to −0.66)
  HbA1c                                  
  Across all studies                     −2.48% (95% CI −2.73 to −2.24)
  Canagliflozin                          −0.81% (95% CI −0.85 to −0.77)
  Dapagliflozin                          −0.81% (95% CI −0.85 to 0.78)
  Empagliflozin                          −1.61% (95% CI −1.70 to −1.52)
  Remogliflozin                          −4.47% (95% CI −4.75 to −4.19)
  Body weight                            
  Across all studies                     −1.88 kg (95% CI −2.11 to −1.66)
  Canagliflozin                          −1.70 kg (95% CI −1.75 to −1.65)
  Dapagliflozin                          −1.05 kg (95% CI −1.09 to 1.01)
  Empagliflozin                          −1.46 kg (95% CI −1.56 to −1.37)
  Eemogliflozin                          −1.19 kg (95% CI −1.34 to −1.04)
  Waist circumference                    
  Across all studies                     −2.89 cm (95% CI −4.32 to −1.46)
  Canagliflozin                          −3.68 cm (95% CI −3.89 to −3.47)
  Dapagliflozin                          0.17 cm (95% CI 0.04‐0.30)
  Empagliflozin                          −3.08 cm (95% CI −3.26 to −2.91)
  Alanine transamidase                   
  Across all studies                     −0.21 IU/L (95% CI −0.33 to −0.10)
  Canagliflozin                          −0.23 IU/L (95% CI −0.30 to 0.16)
  Aspartate transamidase                 
  Across all studies                     0.55 IU/L (95% CI −0.63 to 1.74)
  Canagliflozin                          −0.10 IU/L (95% CI −0.20 to −0.01)
  Creatinine                             
  Across all studies                     0.16 lmol/L (95% CI −0.11 to 0.43)
  Canagliflozin                          0.08 lmol/L (95% CI 0.02‐0.15)
  Dapagliflozin                          0.41 lmol/L (95% CI 0.35‐0.47)
  Estimated glomerular filtration rate   
  Across all studies                     −0.98 mL/\[min·1.73 m^2^\] (95% CI −1.69 to −0.27)
  Canagliflozin                          −0.51 mL/\[min·1.73 m^2^\] (95% CI −0.56 to −0.46)
  Dapagliflozin                          −0.89 mL/\[min·1.73 m^2^\] (95% CI −0.99 to −0.78)
  Empagliflozin                          0.004 mL/\[min·1.73 m^2^\] (95% CI −0.14 to 0.15)
  Urea                                   
  Across all studies                     0.99 mmol/L (95% CI 0.35‐1.64)
  Canagliflozin                          0.01 mmol/L (95% CI −0.08 to 0.06)
  Dapagliflozin                          −0.92 mmol/L (95% CI 0.84‐1.00)

Sensitivity Analysis {#jah32046-sec-0018}
--------------------

In leave‐1‐out sensitivity analyses, the pooled effect estimates remained similar across all studies and their subgroups, which confirmed that the significant difference between the studied groups is the overall effect of all included studies.

Publication Bias {#jah32046-sec-0019}
----------------

Visual inspection of funnel plot symmetry suggested no potential publication bias for the comparison of SBP levels between SGLT2 inhibitor‐treated groups and placebo groups (Figure [4](#jah32046-fig-0004){ref-type="fig"}). However, the presence of publication bias was suggested by Egger linear regression (intercept=−9.01, standard error=2.71; 95% CI=−14.43, −3.59; t=3.31, *df*=71.00, 2‐tailed *P*\<0.001) and Begg rank correlation test (Kendall τ with continuity correction=−0.22, z=2.84, 2‐tailed *P*\<0.001). After adjustment of effect size for potential publication bias using the trim‐and‐fill correction, no potentially missing studies were imputed in funnel plot (WMD −2.46 mm Hg, 95% CI −2.86 to −2.06) (Figure [5](#jah32046-fig-0005){ref-type="fig"}). The fail‐safe N test showed that 2294 studies would be needed to bring the WMD down to a nonsignificant value (*P*\>0.05).

![Funnel plots for publication bias in the studies selected for the analysis of the effects of SGLT2 inhibitors on systolic blood pressure. Open circles represent observed published studies; open diamond represents the observed effect size. SGLT 2, sodium‐glucose cotransporter 2.](JAH3-6-e004007-g004){#jah32046-fig-0004}

![Trim‐and‐fill method (systolic blood pressure) to impute potentially missing studies. No potentially missing study was imputed in funnel plot. Open circles represent observed published studies; open diamond represents the observed effect size; closed diamond represents imputed effect size.](JAH3-6-e004007-g005){#jah32046-fig-0005}

Visual inspection of funnel plot symmetry suggested no potential publication bias for the comparison of DBP levels between SGLT2 inhibitor‐treated groups and placebo groups (Figure [6](#jah32046-fig-0006){ref-type="fig"}); this was in line with Egger linear regression (intercept=−5.69, standard error=3.74; 95% CI=−13.1, 1.7; t=1.52, *df*=63.00, 2‐tailed *P*=0.133) and Begg rank correlation test (Kendall τ with continuity correction=−0.12, z=1.52, 2‐tailed *P*=0.126). After adjustment of the effect size for potential publication bias using the trim‐and‐fill correction, 1 potentially missing study was imputed in funnel plot (WMD −1.50 mm Hg, 95% CI −1.87, −1.13; Figure [7](#jah32046-fig-0007){ref-type="fig"}). The fail‐safe N test showed that 377 studies would be needed to bring the WMD down to a nonsignificant value (*P*\>0.05).

![Funnel plots for publication bias in the studies selected for the analysis of the effects of SGLT2 inhibitors on diastolic blood pressure. Open circles represent observed published studies; open diamond represents the observed effect size. SGLT 2, sodium‐glucose cotransporter 2.](JAH3-6-e004007-g006){#jah32046-fig-0006}

![Trim‐and‐fill method (diastolic blood pressure) to impute potentially missing studies. One potentially missing study was imputed in funnel plot. Open circles represent observed published studies; open diamond represents observed effect size; closed diamond represents imputed effect size; closed circle represent imputed study.](JAH3-6-e004007-g007){#jah32046-fig-0007}

Discussion {#jah32046-sec-0020}
==========

The SGLT2 is a high‐capacity and low‐affinity protein that is abundantly expressed in the most proximal part of the renal tubule and has an important role in the reabsorption of glucose. This systematic review and meta‐analysis suggests that SGLT2 significantly reduces SBP and DBP, although findings have to be interpreted in the context of some moderate level of heterogeneity.

Dapagliflozin was the first SGLT2 inhibitor to be approved for the treatment of patients with T2D, initially in Europe and subsequently in United States and Japan.[67](#jah32046-bib-0067){ref-type="ref"}, [68](#jah32046-bib-0068){ref-type="ref"} Several studies have reported beneficial effects of dapagliflozin on SBP and DBP, especially in patients with T2D.[22](#jah32046-bib-0022){ref-type="ref"}, [36](#jah32046-bib-0036){ref-type="ref"} It has been reported that treatment either as monotherapy or add‐on therapy with another SGLT2 inhibitor such as canagliflozin, empagliflozin, ipragliflozin, luseogliflozin, and tofogliflozin is associated with a small but significant reduction in SBP and DBP.[67](#jah32046-bib-0067){ref-type="ref"} Our findings of the effects of SGLT2 inhibitors on BP are similar to a recent systematic review by Baker et al[69](#jah32046-bib-0069){ref-type="ref"} and a recent meta‐analysis of efficacy and safety of SGLT2 inhibitors.[70](#jah32046-bib-0070){ref-type="ref"}

In addition to their effects on glucose excretion, SGLT inhibitors also inhibit sodium reabsorption in the proximal convoluted tubule.[67](#jah32046-bib-0067){ref-type="ref"} The BP reductions observed with the SGLT2 inhibitors may result from their chronic natriuretic and osmotic diuretic effects. It has been reported that SGLT2 inhibitors increase urinary output by between 107 and 470 mL/d.[69](#jah32046-bib-0069){ref-type="ref"} Therefore, the increased urinary sodium excretion may reduce plasma volume, resulting in reduced BP, particularly with increasing age.[20](#jah32046-bib-0020){ref-type="ref"} Moreover, Imprialos et al have also reported a potential direct natriuretic effect of SGLT2 inhibitors.[67](#jah32046-bib-0067){ref-type="ref"}

Other possible mechanisms accounting for the BP‐lowering effects of SGLT2 inhibitors include nephron remodeling, reduction in arterial stiffness, and the effects on weight loss.[71](#jah32046-bib-0071){ref-type="ref"} SGLT2 inhibitors, in addition to being effective in the treatment of T2D, appear to have benefits beyond glucose lowering, including effects on weight loss and raising high‐density lipoprotein cholesterol levels.[70](#jah32046-bib-0070){ref-type="ref"}, [72](#jah32046-bib-0072){ref-type="ref"} Therefore, SGLT2 inhibitors may play a significant role in reducing cardiovascular risk factors in people with T2D.

Canagliflozin and dapagliflozin inhibit SGLT2 activity in the proximal tubule, blocking the reabsorption of glucose back into the bloodstream. Furthermore, canagliflozin also blocks intestinal SGLT1, thereby reducing glucose absorption, although by a small magnitude.[39](#jah32046-bib-0039){ref-type="ref"} The SGLT2 inhibitors are reported to have different effects on BP. Clar et al reported that dapagliflozin treatment was associated with a reduction in SBP ranging from −1.3 to −7.2 mm Hg in the patients treated with doses of 10 mg.[73](#jah32046-bib-0073){ref-type="ref"} Rosenstock et al reported a reduction in SBP in response to canagliflozin treatment ranging from −0.9 mm Hg with 50 mg once daily to −4.9 mm Hg with 300 mg once daily (compared to −1.3 mm Hg with placebo and −0.8 mm Hg with sitagliptin).[13](#jah32046-bib-0013){ref-type="ref"}

In the different studies we reviewed, patients received the SGLT2 inhibitors against different treatment backgrounds. For example, canagliflozin and dapagliflozin are available with metformin in a combination preparation; empagliflozin is available in a combination preparation with linagliptin (a DPP‐4 inhibitor). The SGLT2 inhibitors (gliflozins) may often be taken with sulfonylureas, pioglitazone, and insulin.

Two large RCTs are currently in progress to assess the cardiovascular safety of the SGLT2 inhibitors. The Canagliflozin Cardiovascular Assessment Study (CANVAS)[74](#jah32046-bib-0074){ref-type="ref"} enrolled patients with T2D at high cardiovascular risk to assess the possible effect of canagliflozin on the incidence of clinical events, and The Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE‐TIMI 58) is a 6‐year trial assessing whether dapagliflozin reduces the risk of the composite endpoint of cardiovascular death, myocardial infarction, or ischemic stroke in patients with T2D.[69](#jah32046-bib-0069){ref-type="ref"} The findings of these 2 large RCTs may elucidate the clinical efficacy of SGLT2 inhibitors and provide a definitive answer on their effects on metabolic parameters, especially cardiovascular‐related metabolic factors.

We acknowledge several limitations in our review and meta‐analysis. First, the majority of the included studies had relatively small sample sizes, potentially leading to unstable estimates of treatment effects, because smaller trials might be methodologically less robust and are prone to report larger effect sizes.[75](#jah32046-bib-0075){ref-type="ref"}, [76](#jah32046-bib-0076){ref-type="ref"} Therefore, the present meta‐analysis may have been underpowered to detect a true effect. Second, the background therapies of participants were not uniform, including the use of metformin monotherapy and metformin in combination with pioglitazone, which might be associated with the heterogeneity of our results. Third, the follow‐up periods were short, and investigation of SGLT2 long‐term efficacy and safety is still necessary. Last, there was some moderate heterogeneity across studies included in meta‐analysis overall and by specific SGLT2 inhibitor that was not explained by differences in the length of follow‐up across studies. However, the pooled estimates showed the same direction of effects across different SGLT2 inhibitors, supporting the clinical plausibility of the effects observed across studies. Possible reasons for the heterogeneity include differences in background treatments and particularly BP‐lowering therapies across studies, which we could not, unfortunately, account for. However, because differences in such therapies would tend to occur randomly, they are unlike to account for the overall effects observed across studies.

Conclusion {#jah32046-sec-0021}
==========

SGLT2 glucose cotransporter inhibitors have a beneficial off‐target effect on BP in T2D patients. They also appear to have effects on other cardiometabolic parameters including lipid profile and body weight. In conclusion, these inhibitors have numerous potentially beneficial clinical effects when used as monotherapy or add‐on therapy with other drugs, especially in patients with T2D and cardiovascular disease. However, our findings should be interpreted with consideration for the moderate statistical heterogeneity across included studies.
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